JP2024543377A5 - - Google Patents

Info

Publication number
JP2024543377A5
JP2024543377A5 JP2024527355A JP2024527355A JP2024543377A5 JP 2024543377 A5 JP2024543377 A5 JP 2024543377A5 JP 2024527355 A JP2024527355 A JP 2024527355A JP 2024527355 A JP2024527355 A JP 2024527355A JP 2024543377 A5 JP2024543377 A5 JP 2024543377A5
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
compound according
groups
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527355A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024543377A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/049426 external-priority patent/WO2023086399A1/en
Publication of JP2024543377A publication Critical patent/JP2024543377A/ja
Publication of JP2024543377A5 publication Critical patent/JP2024543377A5/ja
Pending legal-status Critical Current

Links

JP2024527355A 2021-11-10 2022-11-09 造血前駆体キナーゼの二官能性分解物質およびその治療的使用 Pending JP2024543377A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163263875P 2021-11-10 2021-11-10
US63/263,875 2021-11-10
PCT/US2022/049426 WO2023086399A1 (en) 2021-11-10 2022-11-09 Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
JP2024543377A JP2024543377A (ja) 2024-11-21
JP2024543377A5 true JP2024543377A5 (cg-RX-API-DMAC7.html) 2025-11-07

Family

ID=85132852

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527355A Pending JP2024543377A (ja) 2021-11-10 2022-11-09 造血前駆体キナーゼの二官能性分解物質およびその治療的使用

Country Status (12)

Country Link
US (2) US12091426B2 (cg-RX-API-DMAC7.html)
EP (1) EP4430052A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024543377A (cg-RX-API-DMAC7.html)
KR (1) KR20240101654A (cg-RX-API-DMAC7.html)
CN (1) CN118510786A (cg-RX-API-DMAC7.html)
AR (1) AR127625A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022388571A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235913A1 (cg-RX-API-DMAC7.html)
IL (1) IL312361A (cg-RX-API-DMAC7.html)
MX (1) MX2024005431A (cg-RX-API-DMAC7.html)
TW (1) TW202334170A (cg-RX-API-DMAC7.html)
WO (1) WO2023086399A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
WO2025029995A1 (en) * 2023-08-01 2025-02-06 Arvinas Operations, Inc. Hpk1 targeting compounds and uses thereof
CN117126133B (zh) * 2023-08-14 2026-06-30 中国海洋大学 一种化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031601B1 (ru) 2013-07-31 2019-01-31 Джилид Сайэнс, Инк. Ингибиторы syk
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
US20200038513A1 (en) 2018-07-26 2020-02-06 Arvinas Operations, Inc. Modulators of fak proteolysis and associated methods of use
MX2021001957A (es) 2018-08-22 2021-07-15 Cullgen Shanghai Inc Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk).
EP3873608A1 (en) * 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP4371987B9 (en) * 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
CN114423463B (zh) * 2019-05-06 2025-09-26 西奈山伊坎医学院 作为hpk1的降解剂的异双功能化合物
CN112552293A (zh) * 2019-09-25 2021-03-26 珠海宇繁生物科技有限责任公司 一种protac小分子化合物及其应用
JP7815127B2 (ja) 2020-02-19 2026-02-17 ニューリックス セラピューティクス,インコーポレイテッド インターロイキン-1受容体関連キナーゼの二機能性分解剤およびその治療的使用
TWI918648B (zh) * 2020-05-06 2026-03-21 美商新銳思生物製藥股份有限公司 造血前驅細胞激酶之雙官能降解劑及其治療用途

Similar Documents

Publication Publication Date Title
JP2022509533A5 (cg-RX-API-DMAC7.html)
JP7158577B2 (ja) Pd-1/pd-l1阻害剤
JP7105359B2 (ja) Pd-1/pd-l1阻害剤
JP7273172B2 (ja) Hpk1阻害活性を有する置換6-アザベンゾイミダゾール化合物
JP2024542543A5 (cg-RX-API-DMAC7.html)
US12037342B2 (en) Substituted eneoxindoles and uses thereof
JP2021006568A5 (cg-RX-API-DMAC7.html)
IL268282B2 (en) hiv inhibitory compounds
JP2019528280A5 (cg-RX-API-DMAC7.html)
CA3117556A1 (en) Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
TWI751517B (zh) 類鐸受體調節劑之固體形式
TWI751516B (zh) 類鐸受體調節劑之固體形式
JP2023536663A5 (cg-RX-API-DMAC7.html)
HRP20251374T1 (hr) Prolijekovi nukleotidnih analoga fosfonamida i njihova farmaceutska uporaba
KR20240006683A (ko) TLR8 조절 화합물과 항-HBV siRNA 치료제의 조합물
RU2021135577A (ru) Амидные производные, применимые в лечении инфекции, вызванной hbv, или заболеваний, вызванных hbv
RU2021138956A (ru) Сочлененные гетероциклические производные в качестве противовирусных средств
US20220257619A1 (en) Long-acting formulations of tenofovir alafenamide
HK40047702A (en) Pd-1/pd-l1 inhibitors